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C4d deposition in peritubular capillaries (PTC) reflects complement activation in
antibody-mediated rejection (ABMR) of kidney allograft. However, its association
with allograft survival is controversial. We hypothesized that capillary deposition of
C5b9—indicative of complement-mediated injury—is a severity marker of ABMR.
This pilot study aimed to determine the frequency, location and prognostic impact
of these deposits in ABMR. We retrospectively selected patients diagnosed with
ABMR in two French transplantation centers from January 2005 to December 2014
and performed C4d and C5b9 staining by immunohistochemistry. Fifty-four patients
were included. Median follow-up was 52.5 (34.25–73.5) months. Thirteen patients
(24%) had C5b9 deposits along glomerular capillaries (GC). Among these, seven
(54%) had a global and diffuse staining pattern. Twelve of the C5b9+ patients
also had deposition of C4d in GC and PTC. C4d deposits along GC and PTC
were not associated with death-censored allograft survival (p = 0.42 and 0.69,
respectively). However, death-censored allograft survival was significantly lower in
patients with global and diffuse deposition of C5b9 in GC than those with a segmental
pattern or no deposition (median survival after ABMR diagnosis, 6 months, 40.5
months and 44 months, respectively; p = 0.015). Double contour of glomerular
basement membrane was diagnosed earlier after transplantation in C5b9+ ABMR than
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in C5b9– ABMR (median time after transplantation, 28 vs. 85 months; p = 0.058). In
conclusion, we identified a new pattern of C5b9+ ABMR, associated with early onset
of glomerular basement membrane duplication and poor allograft survival. Complement
inhibitors might be a therapeutic option for this subgroup of patients.
Keywords: antibody-mediated rejection, kidney transplantation, complement, C4d, C5b9
INTRODUCTION
Antibody-mediated rejection (ABMR) is the most common
cause of allograft failure after kidney transplantation (1).
In active ABMR, donor-specific antibodies (DSA) bind to
graft endothelium, and activate complement-dependent
and -independent mechanisms that recruit natural killer
(NK) cells, neutrophils and macrophages which contribute
to inflammatory lesions [peritubular capillaritis (PTC),
glomerulitis], cellular necrosis and thrombotic microangiopathy.
In chronic active ABMR, a repetitive pattern of thrombotic
events and inflammatory changes result in endothelial cell
injury and allograft matrix remodeling, such as transplant
glomerulopathy (2). The complement system plays a key role
in the pathophysiology of ABMR. C4d accumulation along
PTC—which reflects the ability of the DSA bound to the
surface of endothelial cells to activate the classical complement
pathway—is recognized as a tissue footprint marker in ABMR
(3, 4). Several in vitro assays have recently been developed to
test the ability of DSA to bind complement products. Loupy et
al. (5) demonstrated that positive C1q-binding DSA in the first
year after transplantation was associated with poor graft survival.
Sicard et al. (6) observed that positive C3d-binding DSA at the
time of ABMR diagnosis was an independent risk factor for
graft loss. Moreover, Lefaucheur et al. (7) showed that ABMR
in patients with predominant DSA IgG3 subclass—which is the
most able to activate the complement cascade—was associated
with the poorest graft survival.
However, the in vitro complement-fixing ability of DSA
does not reflect complement activation on the endothelial cell
surface and the association between positive C4d staining with
allograft survival remains controversial (8–11). They both do
not indicate ongoing complement-mediated endothelial injury.
Complement regulatory proteins can stop at any step the
complement activation cascade on endothelial cell surface.
In contrast, the deposition of the C5b9 membrane attack
complex indicates complete complement cascade activation.
The terminal pathway directly activates endothelial cells
through sublytic concentrations of C5b9 and/or recruitment of
inflammatory cells by the anaphylatoxins C3a and C5a, and
can also be responsible for endothelial cell lysis (1). However,
in spite of the major role the C5b9 membrane attack complex
plays in this damage, it has never been evaluated in vivo in
kidney allografts.
Abbreviations: ABMR, antibody-mediated rejection; C4d, complement split
product C4d; C5b9, membrane attack complex; cg, double contour of glomerular
basement membrane; DSA, donor-specific antibody; GC, glomerular capillaries;
HLA, human leukocyte antigen; PTC, peritubular capillaries; TCMR, T cell-
mediated rejection.
This study aimed to determine the frequency and location
of C5b9 deposits in a well-phenotyped cohort of patients
experiencing ABMR, and to evaluate their impact on
allograft survival.
METHODS
Patients and Samples
We retrospectively selected transplant recipients with ABMR
from the databases of the Departments of Pathology of two
French University Hospitals (Montpellier and Bordeaux). To be
included, patients had to be over 18 years and have undergone
a renal biopsy that fulfilled criteria for a first histological
diagnosis of (acute or chronic active) ABMR according to
Banff 2015 classification from January 2008 to December 2013
at Montpellier Hospital and from January 2005 to December
2014 at Bordeaux Hospital, with positive DSA at time of
biopsy. All biopsies were performed for cause: elevation of
serum creatinine (>20% compared to baseline value) and/or
a urine protein-to-creatinine ratio >50 mg/mmol. Complete
immunofluorescence with anti-IgA, -IgG, -IgM, -C3, -C1q, -
Kappa and -Lambda on frozen sections was performed in all
patients. Exclusion criteria were the following: no serological
evidence of anti-HLA DSA, insufficient renal tissue sample for
further immunohistochemistry (i.e.,<2 non-sclerosed glomeruli
in each recut section), ABO-incompatible transplantation,
combined transplantation, thrombotic microangiopathy and
concomitant recurrent or de novo glomerulonephritis. The
Institutional Review Board of Montpellier University Hospital
approved this study (approval number: DC-2015-2473). All
patients provided written informed consent to participate.
Immunohistochemical Staining for C4d
and C5b9
Staining for C4d and C5b9 was performed for all biopsies
by immunohistochemistry. Briefly, paraffin-embedded sections
were retrieved and cut at a thickness of 3-µm, deparaffinized
and subjected to antigen retrieval. After blocking endogenous
peroxidases, the sections were incubated with the relevant
primary antibody. Binding of the primary antibody was
visualized using the appropriate horseradish peroxidase-labeled
secondary antibody and diaminobenzidine as the chromogen.
Finally, the sections were counterstained with hematoxylin. The
primary antibodies included rabbit monoclonal anti-human C4d
(DB107, clone A24-T, dilution 1/100; DB Biotech) and mouse
monoclonal anti-human C9 neoepitope (clone B7, dilution
1/50000; gift from Paul Morgan, Cardiff, United Kingdom),
which is very specific to C5b9 fixation in membrane. C9
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FIGURE 1 | Flow chart. ABMR, antibody-mediated rejection; HLA, human leukocyte antigen; DSA, donor-specific antibody; IHC, immunohistochemistry.
neoepitope detection was enhanced by the EnVision FLEX kit
with linker (Dako).
The optimum antibody dilution and incubation were
determined empirically for each primary antibody by performing
a titration experiment and serial dilutions on positive
(class 4 lupus nephritis) and negative controls (peritumoral
kidney tissue).
The stained sections were evaluated by two renal pathologists
who were blinded to the clinical and serological data. The
sections were scored according to the presence of complement
deposits along the PTC and glomerular capillaries (GC) of non-
sclerosed glomeruli. Complement deposits in the glomerular
mesangium and at the vascular pole were not taken into account.
C4d and C5b9 deposition in the PTC were scored as minimal
(>0 but<10% of PTC), focal (10–50% of PTC) or diffuse (>50%
of PTC). C4d and C5b9 deposition in the GC were scored as
segmental (<50% of capillary loops of all affected glomeruli) or
global (≥50% of the capillary loops of at least 1 glomerulus) and
focal (at least 1 glomerulus but <50% of glomeruli) or diffuse
(≥50% of glomeruli). The staining intensity was evaluated using
a semi-quantitative scoring system (negative = 0, weak = +,
moderate=++ and strong=+++).
Detection of Donor-Specific Antibodies
All patients were tested for circulating donor-specific anti-HLA
-A, -B, -Cw, -DR, -DQA1, -DQB1, and -DP antibodies in serum
samples obtained at the time of biopsy using single antigen flow
bead assays (One Lambda) on a Luminex platform. All beads
showing a normalized mean fluorescence intensity >500 were
considered positive.
Statistical Analysis
Quantitative variables were expressed as a mean with standard
deviation or median with first and third quartiles. Qualitative
variables were expressed by counts and percentages. We
compared means, medians and percentages using the Student’s
t-test (or Wilcoxon test when appropriate) and chi-square test
with Yates’s correction (or Fisher’s exact test when appropriate).
Kidney allograft survival was assessed by the Kaplan-Meier
method and compared among the groups with the log-rank
test. Kidney allograft survival was calculated from the date of
the ABMR-defining biopsy to the date of allograft loss (return
to dialysis or new transplantation). If a patient died with a
functioning graft, graft survival was censored at the time of death.
Cox proportional-hazards models were used to estimate the
hazard ratios (HR) and 95% confidence intervals (CI) for death-
censored allograft loss. The association of clinical, functional,
immunological and histological parameters with allograft loss
was assessed with univariate Cox regression analyses. A P-value
< 0.05 was used to select variables that were then entered
into a single multivariate Cox model with stepwise backward
elimination. R software (version 3.2.0) was used to perform all
analyses. All tests were two-sided and P-values < 0.05 were
considered statistically significant.
RESULTS
Patient Characteristics
During the study period, 122 patients (55 at Montpellier Hospital
and 67 at Bordeaux Hospital) had a first histological diagnosis
of ABMR of the current graft according to Banff 2015 criteria
(4). Among them, 68 were excluded for the following reasons: no
serological evidence of anti-HLADSA (n= 27), insufficient tissue
material for C4d and C5b9 detection by immunohistochemistry
(n = 27), ABO-incompatible transplantation (n = 1), combined
transplantation (n = 2), thrombotic microangiopathy (n = 6)
and concomitant recurrent or de novo glomerulonephritis (n =
5). Finally, 54 patients were included (Figure 1), with a median
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TABLE 1 | Patient characteristics.
Variable n Value
Recipient characteristics
Age (years), median (Q1–Q3) 54 49.5 (35–59)
Male sex, n (%) 54 34 (63)
Nephropathy, n (%) 53
Glomerulonephritis 21 (40)
Autosomal dominant polykystosis 6 (11)
Interstitial nephritis 3 (6)
Malformative uropathy 8 (15)
Others 5 (9)
Unknown 10 (19)
Blood group: A/B/AB/O, n 53 29/4/0/20
Time since dialysis (months), median (Q1–Q3) 50 30.5
(12–44.75)
Transplant baseline characteristics
Preemptive, n (%) 52 4 (8)
Transplant number >1, n (%) 54 19 (35)
Deceased donor, n (%) 54 49 (91)
Expanded criteria donor, n (%) 54 16 (30)
Cold ischemia time (minutes), mean ± SD 50 1074.62 ±
540.78
Delayed graft function, n (%) 47 12 (26)
HLA A/B/DR mismatches, median (Q1–Q3) 52 4 (3–5)
Immunosuppressive protocol
Induction therapy, n (%) 53
Anti-thymocyte globulin 31 (58)
IL-2 receptor antagonist 21 (40)
Plasmapheresis 3 (6)
Intravenous immunoglobulin 6 (11)
Rituximab 3 (6)
Regimen at the time of biopsy 54
None/ciclosporine/tacrolimus/mTORi, n 1/19/22/12
None/mycophenolic acid/azathioprine, n 5/46/3
Steroid withdrawal, n 12 (22)
Biology at the time of biopsy 54
Creatininemia (µmol/l), median (Q1–Q3) 54 178 (140–223)
eGFR, MDRD formula (ml/min/1 m732),
mean +/− SD
54 34.31 ± 17.71
Urine protein-to-creatinine ratio (mg/mmol),
median (Q1–Q3)
45 34 (19–121)
Characteristics of anti-HLA DSA at the time of biopsy
Class I, n (%) 54 31 (57)
Class II, n (%) 53 47 (89)
Class I + II, n (%) 53 24 (45)
Immunodominant DSA
Class I, n (%) 53 12 (23)
Class II, n (%) 53 41 (77)
MFI, median (Q1–Q3) 52 9000 (4365.5–
14125)
Rejection treatment
Steroid pulses, n (%) 52 47 (90)
Switch to tacrolimus, n (%) 54 15 (28)
(Continued)
TABLE 1 | Continued
Variable n Value
Plasmapheresis, n (%) 54 46 (85)
Intravenous immunoglobulin, n (%) 54 43 (80)
Rituximab, n (%) 52 30 (58)
Graft loss, n (%) 54 33 (61)
Death, n (%) 54 6 (11)
Follow-up (months), median (Q1–Q3) 54 52.5
(34.25–73.5)
Q1, first quartile 1; Q3, third quartile; HLA, human leukocyte antigen; DSA, donor-specific
antibody; MFI, mean fluorescence intensity; eGFR, estimated glomerular filtration rate;
MDRD, modification of diet in renal disease; mTORi, mammalian target of rapamycine
inhibitor.
Definitions: delayed graft function, dialysis within the first week after transplantation;
expanded criteria donor, donor age > 60 years or 50 to 59 years with 2 of the following
criteria: high blood pressure, cerebrovascular death cause, creatininemia> 132.6 µmol/l.
follow-up of 52.5 months (range, 34.25–73.5 months). Their
characteristics are summarized in Table 1. The median age of the
patients was 49.5 years (35–59). Fifty patients (91%) had received
their transplant from a deceased donor. Thirty-one patients
(58%) had undergone an induction therapy with rabbit anti-
thymocyte globulins. At the time of ABMR diagnosis, the mean
estimated glomerular filtration rate was 34.31 ± 17.71 ml/min/1
m732, and the median proteinuria level was 34 mg/mmol (19–
121). Thirty-one (57%) patients had class I anti-HLA DSA; 47
(89%) had class II anti-HLA DSA; and 24 (45%) had class I and
II anti-HLA DSAs. The immunodominant anti-HLA DSAs were
class I in 12 (23%) patients and class II in 41 (77%) patients with
a mean fluorescent intensity of 9000 (4365.5–14125).
Histological Parameters of ABMR-Defining
Biopsies
The median time of ABMR diagnosis after transplantation was
37.5 months (range, 6.25–76 months). Twenty-eight patients
(52%) had acute ABMR and 26 (48%) had chronic active
ABMR, with double contour of glomerular basement membrane.
Nineteen patients (35%) had a concomitant T-cell mediated
rejection. Positive C4d along PTC was found in 23/28 patients
(82%) with acute ABMR and 21/26 (81%) with chronic active
ABMR. Forty-five patients (85%) had interstitial fibrosis and
tubular atrophy score ≥1. All histological parameters are listed
in Table 2.
Positivity and Location of C4d and C5b9
Deposits on ABMR Biopsies
The findings are summarized in Table 3. C4d was positive in
PTC of 44/54 biopsies (81%) and in GC of 48/54 (89%). The
deposition of C4d in PTC was minimal in 3/54 biopsies (6%),
focal in 11/54 (20%), and diffuse in 30/54 (56%). The staining was
weak in 3/44 patients (7%), moderate in 11/44 (25%) and strong
in 30/44 (68%). Glomerular C4d deposition was pseudolinear
and located in the subendothelial space and/or in the glomerular
basement membrane (Figure 2). Deposition was segmental and
focal in 4/54 biopsies (7%), segmental and diffuse in 3/54 (6%)
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TABLE 2 | Histological parameters of ABMR-defining biopsies.
Variable n Value
Time after transplantation (months), median
(Q1–Q3)
54 37.5 (6.25–76)
Number of glomeruli, median (Q1–Q3) 54 10 (6–14)
Concomitant T-cell mediated rejection, n (%) 54 19 (35)
Banff scores
Glomerulitis (g) score 54
≥1, n (%) 34 (63)
Median (Q1–Q3) 1 (0–2)
Mesangial matrix expansion (mm) score 54
≥1, n (%) 31 (57)
Median (Q1–Q3) 1 (0–1)
Double contour (cg) score 54
≥1, n (%) 26 (48)
Median (Q1–Q3) 0 (0–2)
Interstitial fibrosis and tubular atrophy (IFTA)
score
54
≥1, n (%) 46 (85)
Median (Q1–Q3) 1 (1–2)
Interstitial inflammation (i) score 54
≥1, n (%) 43 (80)
Median (Q1–Q3) 1 (1–2)
Tubulitis (t) score 54
≥1, n (%) 19 (35)
Median (Q1–Q3) 0 (0–1)
Peritubular capillaritis (ptc) score 54
≥1, n (%) 50 (93)
Median (Q1–Q3) 2 (1–2)
Arteriolar hyalinosis (ah) score 54
≥1, n (%) 36 (67)
Median (Q1–Q3) 1 (0–1)
Vascular fibrous intimal thickening (cv) score 48
≥1, n (%) 28 (58)
Median (Q1–Q3) 1 (0–1.25)
Vasculitis (v) score 48
≥1, n (%) 6 (12)
Median (Q1–Q3) 0 (0–0)
Microvascular inflammation (g + ptc) score 54
≥2, n (%) 41 (76)
Median (Q1–Q3) 2 (2–3)
C4d deposition in peritubular capillaries ≥2
(IF)
52 35 (67)
ABMR, antibody-mediated rejection; Q1, first quartile; Q3, third quartile; IF,
immunofluorescence.
and global and diffuse in 41/54 (76%). The staining was weak
in 12/48 patients (25%), moderate in 12/48 (25%) and strong in
24/48 (50%).
C5b9 was positive in PTC of one patient (1.8%) and in GC of
13/54 biopsies (24%). Glomerular C5b9 deposition was granular
and subendothelial (Figure 2). Deposition was segmental and
focal in 4/54 biopsies (7%), segmental and diffuse in 2/54 (4%)
and global and diffuse in 7/54 (13%). Glomerular C5b9 staining
TABLE 3 | Location and intensity of C4d and C5b9 deposits by
immunohistochemistry on ABMR biopsies (n = 54).
C4d C5b9
Peritubular capillaries, n (%)
Positive staining 44 (81) 1 (2)
Distribution
Negative 10 (19) 53 (98)
Minimal 3 (6) 0 (0)
Focal 11 (20) 1 (2)
Diffuse 30 (56) 0 (0)
Intensity of positive Staining
Weak (+) 3 (7) 0 (0)
Moderate (++) 11 (25) 1 (100)
Strong (+++) 30 (68) 0 (0)
Glomerular capillaries, n (%)
Positive staining 48 (89) 13 (24)
Distribution
Negative 6 (11) 41 (76)
Segmental and focal 4 (7) 4 (7)
Segmental and diffuse 3 (6) 2 (4)
Global and diffuse 41 (76) 7 (13)
Intensity of positive staining
Weak (+) 12 (25) 12 (92)
Moderate (++) 12 (25) 1 (8)
Strong (+++) 24 (50) 0 (0)
was weak in 12/13 patients (92%) and moderate in one (8%). All
but one of the biopsies with positive glomerular C5b9 deposition
had C4d deposition in PTC (1 focal and 11 diffuse) and in GC (3
segmental and diffuse and 10 global and diffuse). Only one biopsy
had C5b9 deposition in PTC associated with diffuse deposition of
C4d in PTC and global and diffuse deposition of C4d and C5b9
in GC. Among the patients with global and diffuse deposition of
C5b9 in GC, all except one had strong (+++) C4d staining along
GC and PTC (Figure S1).
Death-Censored Allograft Survival After
ABMR Diagnosis According to the
Deposition of C4d and C5b9
During a median follow-up of 52.5 months (range, 34.25–73.5
months), 33 patients (61%) lost their graft. Overall median death-
censored allograft survival after ABMR diagnosis was 43 months
(range, 29–59 months). Graft survival rates were respectively
83.3, 75.9, 70.1, and 27.2% at 3 months, 1 year, 2 years, and
5 years.
C4d deposits in PTC andGCwere not associated with allograft
survival (p = 0.42 and 0.69 by log-rank-test, respectively).
However, death-censored allograft survival was significantly
lower in patients with global and diffuse deposition of C5b9 in
GC than in those with a segmental pattern or no deposition
(median survival after ABMR diagnosis: 6 months, 40.5 months,
and 44months respectively; p= 0.015 by log-rank-test; Figure 3).
Graft survival rates in patients with global and diffuse deposition
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FIGURE 2 | Location of C4d and C5b9 deposits by immunohistochemistry. (A1–A4) ABMR biopsy and (B1,B2) normal biopsy. (A1) C4d staining (x20), (A2,B1) C4d
staining (x40), (A3) C5b9 staining (x20) and (A4,B2) C5b9 staining (x40). (A1,A2) In ABMR biopsy, C4d deposits were located in peritubular capillaries and along the
glomerular capillaries (strong intensity), in the subendothelial space and/or intramembranous (pseudolinear pattern). (A3,A4) C5b9 staining was negative in peritubular
capillaries and positive in glomerular capillaries (weak intensity), in the subendothelial space (granular pattern). There was no mesangial deposit. Positive staining in
tubular basement membranes and Bowman’s capsule are of non-specific significance. (B1,B2) C4d and C5b9 staining was negative in the normal biopsy. Arteriolar
deposits are of non-specific significance.
of C5b9 in GC were respectively 57.1, 42.9, and 28.6% at 3
months, 1 year and 2 years, compared to 85.4, 78.1, and 75.6%
in patients without C5b9 deposit.
In a univariate Cox regression model (Table S1), the HR
for death-censored allograft loss was 3.35 (95% CI, 1.46 to
9.60, p = 0.006) in patients with global and diffuse deposition
of C5b9 in GC. In a multivariate analysis, this association
was not found and the only independent risk factor for
graft loss was the presence of double contour of glomerular
basement membrane (adjusted HR 2.28, 95% CI 1.08 to 4.81,
p= 0.03; Table S2).
Phenotype of ABMR With Global and
Diffuse Deposition of C5b9 in Glomerular
Capillaries
Comparison of C5b9+ and C5b9– ABMR phenotypes is detailed
inTable 4. The time to occurrence of ABMR after transplantation
was not different between C5b9+ and C5b9– ABMR [28 (16–
75) months vs. 39 (5.5–73.5) months, p = 0.75]. C5b9+ ABMR
was associated with a worse graft function at diagnosis (median
estimated glomerular filtration rate, 26 vs. 34 ml/min/1 m732, p
= 0.04) and tended to be associated with more anti-HLA DSA
[3 (2–3.5) vs. 2 (1–3), p = 0.09), without any other difference
in DSA characteristics. The occurrence of de novo DSA was
similar in C5b9+ ABMR to C5b9– ABMR [4/5 (80%) vs. 22/30
(73%), p = 1.00], in the population (n = 35) who had been
screened for anti-HLA antibodies by solid-phase assay before
transplantation. All ABMR with global and diffuse deposition of
C5b9 in GC had diffuse deposition of C4d in PTC and global and
diffuse deposition of C4d in GC. Moreover, all of them displayed
double contour of glomerular basementmembrane, with a higher
mean Banff score at diagnosis than that found in C5b9– ABMR
(1.71 ± 0.95 vs. 0.77 ± 1.05, p = 0.01; Figure 4). These double
contours were diagnosed earlier after transplantation in C5b9+
ABMR than in C5b9– ABMR (median time after transplantation,
28 vs. 85 months; p = 0.058; Figure 5). Among the patients
with double contours, those with global deposits of C5b9
along GC were associated with a trend toward a worse death-
censored allograft survival than the others (median survival
after ABMR diagnosis, 6 vs. 29 months, p = 0.078 by log-rank
test; Figure S2).
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FIGURE 3 | Death-censored graft survival after ABMR diagnosis according to the deposition of C5b9 in glomerular capillaries. ABMR, antibody-mediated rejection;
segmental C5b9+, segmental (focal or diffuse) deposition of C5b9 in glomerular capillaries; global and diffuse C5b9+, global and diffuse deposition of C5b9 in
glomerular capillaries.
DISCUSSION
This is the first study to evaluate C5b9 deposits in human
kidney allografts with ABMR. In a cohort of 54 well-phenotyped
kidney transplant recipients with ABMR from two centers, we
observed that these deposits were present in a subgroup of
patients, mainly located in the glomeruli and always associated
with C4d deposits. ABMR with global and diffuse deposition of
C5b9 in GC constituted a severe phenotype, with worse graft
function at diagnosis and poor allograft survival. C5b9+ ABMR
seems to be associated with early onset of glomerular basement
membrane duplication and accelerated development of chronic
glomerular lesions.
C4d deposition in PTC—a marker of active ABMR—is a
footprint of the activation of the classical complement pathway
after the binding of DSA to mismatched endothelial antigens
(3, 4). In this study, about 80% of the patients had positive C4d
in PTC and nearly 90% a pseudolinear deposition of C4d in
GC. Interestingly, all the patients with C4d deposits along PTC
had C4d in GC. The role of glomerular C4d in ABMR is not
clearly established. The location of C4d deposits along glomerular
endothelial cells, the negativity of C4d staining in T-cell mediated
rejection and protocol graft biopsies (data not shown), and the
strong association with positive C4d staining along PTC in our
population supports the hypothesis that glomerular C4d plays a
role in the pathogenesis of ABMR. Valente et al. (12) previously
found similar results. In their study, glomerular C4d deposits
along endothelial cells were present in cases of acute ABMR
and correlated with C4d positivity along PTC. It is important
to note here that in our study, patients were excluded if they
had chronic/acute thrombotic microangiopathy associated with
ABMR (13), immune complex-mediated glomerulonephritis and
complement disease recurrence (14), because they are also
associated with glomerular C4d positivity.
The endothelial C4d staining in ABMR reflects the first step
of complement activation by the classical complement pathway.
Although C4d staining in PTC is a helpful tool for diagnosing
ABMR, its association with graft survival is controversial (10). In
our study, C4d deposits along PTC and GC were not associated
with graft survival. C4d is an inactive molecule, which has never
been associated with endothelial injury in vitro and can also
indicate a limited complement activation (15). The activation of
the complement cascade is in fact tightly regulated by several
fluid phase and membrane-bound proteins (16). Complete
complement cascade activation up to the terminal pathway—
expressed by positive C5b9 staining—can reflect overactivation
of the complement system, defective complement regulatory
proteins or an imbalance between activation and regulation. In
our study, C5b9 deposits were positive in 24% of the ABMR
biopsies, mainly along GC. All C5b9+ ABMR had positive C4d
staining along PTC and GC indicating initiation by the classical
complement pathway and full complement cascade activation.
The fact that C5b9 was mainly positive in glomeruli and along
with C4d deposits, supports the role of glomerular complement
activation in the pathogenesis of ABMR. Of note, C5b9 is also
often positive in glomeruli, but not in PTC, in thrombotic
microangiopathy (13).
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TABLE 4 | Comparison of functional, immunological and histological variables in the two patterns of antibody-mediated rejection.
Variables n C5b9– ABMR (n = 47) C5b9+ ABMR* (n = 7) P-value
Time after transplantation (months), median (Q1–Q3) 54 39 (5.5–73.5) 28 (16–75) 0.75
Functional (Biology at the Time Of Biopsy)
Creatininemia (µmol/l), median (Q1–Q3) 51 169 (139–212) 258 (197–304) 0.07
eGFR, MDRD formula (ml/min/1 m732), median
(Q1–Q3)
54 34 (27–45.5) 26 (13.5–31) 0.04
Urine protein-to-creatinine ratio (mg/mmol), median
(Q1–Q3)
45 34 (19–121) 58 (25.5–210) 0.78
Immunology
DSA
Number, median (Q1–Q3)
52 2 (1–3) 3 (2–3.5) 0.09
Class I, n (%) 53 25 (53) 6 (86) 0.22
Class II, (n%) 53 41 (89) 6 (86) 1.00
Class I + II, n (%) 53 19 (41) 5 (71) 0.28
Immunodominant DSA
Class I, n (%) 53 10 (22) 2 (29) 0.65
Class II, n (%) 53 36 (78) 5 (71) 0.65
MFI, median (Q1–Q3) 52 9000 (3500–14000) 10335 (7142–13446.5) 0.52
Histology
Concomitant TCMR, n (%) 54 17 (36) 2 (29) 1.00
Glomerulitis (g) score 54
≥1, n (%) 30 (64) 4 (57) 1.00
Median score (Q1–Q3) 1 (0–2) 1 (0–1.5) 0.92
Mesangial matrix expansion (mm) score 54
≥1, n (%) 25 (53) 6 (86) 0.22
Median score (Q1–Q3) 1 (0–1) 1 (1–2) 0.13
Double contour (cg) score 54
≥1, n (%) 19 (40) 7 (100) 0.01
Median score (Q1–Q3) 0 (0–2) 1 (1–2.5) 0.01
Score, n (%) 0.002
0 28 (60) 0 (0)
1 6 (13) 4 (57)
2 9 (19) 1 (14)
3 4 (9) 2 (29)
Interstitial fibrosis and tubular atrophy (IFTA) score 54
≥1, n (%) 40 (85) 6 (86) 1.00
Median score (Q1–Q3) 1 (1–2) 1 (1–1) 0.49
Interstitial inflammation (i) score 54
≥1, n (%) 38 (81) 5 (71) 0.62
Median score (Q1–Q3) 1 (1–2) 1 (0.5–2) 0.91
Tubulitis (t) score 54
≥1, n (%) 17 (36) 2 (29) 0.62
Median score (Q1–Q3) 0 (0–1) 0 (0−0.5) 0.63
Peritubular capillaritis (ptc) score 54
≥1, n (%) 91% (43) 7 (100) 1.00
Median score (Q1–Q3) 2 (1–2) 2 (1–2) 0.99
Arteriolar hyalinosis (ah) score 54
≥1, n (%) 30 (64) 6 (86) 0.40
Median score (Q1–Q3) 1 (0–1) 1 (1–1) 0.65
Vascular intimal fibrous thickening (cv) score 48
≥1, n (%) 23 (55) 5 (83) 0.38
(Continued)
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TABLE 4 | Continued
Variables n C5b9– ABMR (n = 47) C5b9+ ABMR* (n = 7) P-value
Median score (Q1–Q3) 1 (0–1) 1.5 (1–2) 0.14
Vasculitis (v) score 48
≥1, n (%) 6 (14) 0 (0) 1.00
Median score (Q1–Q3) 0 (0–0) 0 (0–0) 0.39
Deposition of C4d in capillaries (IHC), n (%) 54
Glomerular capillaries 0.85
No deposition 6 (13) 0 (0)
Segmental and focal 4 (9) 0 (0)
Segmental and diffuse 3 (6) 0 (0)
Global and diffuse 34 (72) 7 (100)
Peritubular capillaries
None/minimal/focal/diffuse 10/3/11/23 0/0/0/7 0.15
C5b9 deposition in peritubular capillaries (IHC) 0 (0) 1 (14) 0.13
*C5b9+ ABMR, antibody-mediated rejection with global and diffuse deposition of C5b9 in glomerular capillaries.
Q1, first quartile; Q3, third quartile; eGFR, estimated glomerular filtration rate; MDRD, modification of diet in renal disease; DSA, donor-specific antibody; MFI, mean fluorescence intensity;
TCMR, T-cell mediated rejection; IHC, immunohistochemistry.
Global and diffuse glomerular deposition of C5b9—which
reflects unregulated complement activation or a massive
production of complement products due to an excessive
complement activation—occurred in 13% of ABMR in our study,
andwas associated withmassive C4d deposits along PTC andGC.
This characterizes a severe phenotype, with poor graft function
at diagnosis and poor allograft survival. A trend for a higher
number of DSA was the only factor we found to explain this
uncontrolled injury. However, endothelial susceptibility to injury
cannot be excluded, maybe secondary to a lack of complement
regulatory proteins. Indeed, patients with segmental deposition
of C5b9 in GC—which reflects partially regulated complement
activation—had a similar graft survival than patients without
C5b9 deposits—which reflects regulated complement activation.
Moreover, the absence of C5b9 deposits along PTC could suggest
a better complement regulation or the inability to form a
membrane complex attack in these small vessels. Finally, it
is important to note that although glomerular C5b9 staining
was often weak, it was very specific because we used a mouse
monoclonal anti-human C9 neoepitope—which is specific to
C5b9 fixation in membrane—and it was strictly negative in
negative controls. Moreover, in opposition with the intensity
of C4d staining, the weakness of C5b9 staining is probably
the reflection of the regulation of complement activation by
endothelial cells after the cleavage of C4.
Multivariate analysis did not confirm that global and diffuse
deposition of C5b9 in glomerular capillaries was associated
with poor graft survival. The only independent risk factor for
graft loss was the presence of double contours of glomerular
basement membrane, which was associated with more than
a 2-fold risk of graft loss. This result could be explained by
a lack of power (there was a trend toward a lower graft
survival in cg+ C5b9+ ABMR than cg+ C5b9-) but also by
the fact that all patients with global and diffuse C5b9 deposits
had double contours. This lesion is widely accepted to be a
major prognostic factor in ABMR, possibly the most important
one (17, 18). The pathogenesis of transplant glomerulopathy—
currently viewed as a cardinal histological lesion of chronic
ABMR—remains unclear (19). Recently, Gasim et al. (20)
found that pseudolinear GC C4d correlated with the severity
of glomerular basement membrane duplication by light and
electron microscopy. The authors hypothesized that complement
activation could be involved in this multi-layering process.
However, C5b9 staining was not performed in this study. In
our cohort, we observed that 25/26 (96%) patients with double
contours had C4d deposition in GC indicating complement
activation. Strikingly, patients who also had global and diffuse
C5b9 deposits had fast onset of double contours, suggesting
devastating endothelial injury. C5b9 can activate endothelial
cells at sublytic concentrations and induce a pro-inflammatory
state, mainly through non-canonical nuclear factor-κB signaling
(21, 22). Owing to the observational nature of this study, we
cannot confirm a causal link between C5b9 and double contours.
Nethertheless we hypothesize that C5b9 can activate glomerular
endothelial cells and accelerate the duplication of glomerular
basement membrane, because we diagnosed double contours
earlier in C5b9+ ABMR than in C5b9- ABMR and there
was a trend toward a worse death-censored allograft survival
in C5b9+ ABMR among the patients with double contours
This could be a result of repeated episodes of endothelial
activation, injury, and repair (19). However, the duplication
of glomerular basement membrane is not specific of chronic
ABMR. It has been largely described in complement-mediated
diseases such as chronic thrombotic microangiopathy and
membranoproliferative glomerulonephritis (13, 14), which were
excluded in our study.
It is important to note that C5b9 was positive in a subgroup
of patients, indicating that complement activation is often
efficiently regulated. Endothelial injury can also be secondary to
another complement-mediated mechanism—the recruitment of
Frontiers in Immunology | www.frontiersin.org 9 March 2019 | Volume 10 | Article 235
Goutaudier et al. C5b9 Deposition in Antibody-Mediated Rejection
FIGURE 4 | Comparison of histogical features in the two patterns of antibody-mediated rejection. The following Banff scores were compared: (A) microvascular
inflammation [sum of the Banff scores for glomerulitis and peritubular capillaritis], (B) C4d deposition in peritubular capillaritis, (C) double contour of glomerular
basement membrane, (D) interstitial inflammation and tubulitis, (E) interstitial fibrosis and tubular atrophy, and (F) vascular intimal fibrous thickening. Each of these
scores ranges from 0 to 3, with higher score indicating more severe abnormality. The T bars indicate standard errors. ABMR C5b9−, antibody-mediated rejection
without global and diffuse deposition of C5b9 in glomerular capillaries; ABMR C5b9+, antibody-mediated rejection with global and diffuse deposition of C5b9 in
glomerular capillaries.
inflammatory cells by the anaphylatoxins C3a and C5a—and/or
to complement-independent mechanisms, such as antibody-
dependent cell cytotoxicity and direct endothelial cell activation
by the antigen-binding fragment of DSA (23). This relatively
uncommon positivity of C5b9 could explain the conflicting
results of anti-C5 therapies in the prevention and treatment
of ABMR in unselected cohorts (24–26). To reassess the
value of this therapy in ABMR, it could be helpful to select
patients on the basis of demonstrated complement-mediated
endothelial injury.
This study has limitations. Firstly, it was retrospective, and
a significant number of patients were excluded for missing
data (mostly insufficient tissue on recut biopsy sections).
Secondly, we probably underestimated C4d-negative ABMR.
Frontiers in Immunology | www.frontiersin.org 10 March 2019 | Volume 10 | Article 235
Goutaudier et al. C5b9 Deposition in Antibody-Mediated Rejection
FIGURE 5 | Cumulative incidence of cg diagnosis after transplantation according to the deposition of C5b9 in glomerular capillaries. cg, double contour of glomerular
basement membrane; ABMR C5b9–, antibody-mediated rejection without global and diffuse deposition of C5b9 in glomerular capillaries; ABMR C5b9+,
antibody-mediated rejection with global and diffuse deposition of C5b9 in glomerular capillaries.
This is because, prior to the Banff 2013 classification, C4d
was mandatory for a diagnosis of ABMR (27). As our
study inclusion period started in 2008, some cases of C4d-
negative ABMR might not have been classified as ABMR and
therefore not included. Thirdly, all biopsies were performed
for cause, so we did not study subclinical ABMR, which
is also closely associated with graft survival (28). Lastly,
unfortunately we were not able to study ultrastructural changes
of glomerular basement membrane by electronic microscopy,
complement abnormalities nor complement-binding
DSA abilities.
In conclusion, we have defined a new pattern of ABMR of
renal allografts with complete complement cascade activation
up to the terminal pathway in a subgroup of patients. This
constitutes a severe phenotype, with diffuse deposits of C4d
along PTC, C4d/C5b9 along GC, early onset of glomerular
basement membrane duplication and poor allograft survival.
It could be interesting to analyze C4d and C5b9 deposits in
cases of subclinical ABMR to evaluate if their positivity precedes
the occurrence of double contours. Moreover, the value of
anti-C5 therapies in this specific subgroup of patients should
be assessed.
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